Hims & Hers Health enters its August 3 earnings report in a genuinely unusual place: short sellers have been cutting positions for weeks, yet options traders just turned more defensive than they've been in months.
The short side tells a story of slow retreat. At 26.6% of the free float, short interest remains heavily elevated — but it has fallen roughly 9% from its late-June peak near 64 million shares, edging lower almost every session through July. That gradual unwind matters because it removes some of the reflexive squeeze fuel that might otherwise amplify a positive earnings reaction. The borrow market has loosened noticeably alongside it. Availability has climbed to around 48% of outstanding short interest — tight by most standards, but a dramatic improvement on the sub-5% readings seen in mid-June, when finding shares to borrow was nearly impossible. Cost to borrow has ticked up about 23% on the week to 0.82%, but that remains a very cheap rate for a stock this heavily shorted, signalling no real stress in the lending pool. The ORTEX short score, at 69.8, has crept steadily higher through July even as short interest fell, a divergence worth watching ahead of the print.
Options traders broke with the recent calm on Thursday. The put/call ratio jumped to 0.65 — more than two standard deviations above its 20-day mean of 0.59 — reaching the highest defensive reading in recent weeks. That spike broke a month-long pattern of unusually subdued hedging activity. It lands the day before a quiet weekend ahead of an August 3 report, which historically has delivered sharp moves: the May print sent the stock down 11% on the day and another 21% over the following five sessions, while the June report saw a 3.5% drop followed by a 28% recovery over the week. The range of outcomes has been extreme, and options traders appear to be buying that volatility back.
Analyst sentiment has shifted more constructively in July, even if conviction remains mixed. Citigroup raised its target to $35 from $28 on July 23, while BofA nudged its target to $37 the week before — both firms staying at Neutral. Canaccord, carrying a Buy, moved its target to $40 from $32 at the start of the month. The mean consensus target of around $29.77 sits just below the current price of $32.74, which signals that the median analyst still sees the stock as slightly overextended — a notable dynamic going into a binary event. The bull case rests on momentum from the Wegovy pill launch and the Novo Nordisk partnership driving subscriber growth. Bears point to that same concentration risk: heavy reliance on one partner, regulatory uncertainty around compounded GLP-1s, and questions about whether profitability can hold up as competition intensifies. The EPS factor picture is split — 30-day EPS momentum ranks in the 91st percentile, a sharp improvement, while the 90-day figure sits in just the 4th percentile, reflecting how recently the estimates started recovering.
Insider activity adds a layer of caution. The CFO sold shares on July 6 and again on July 17, the COO, CTO, and Chief Medical Officer all sold in June, and the Principal Accounting Officer sold across three consecutive sessions in mid-June. The net 90-day position shows a positive number only because of an award grant; the open-market selling across multiple executives at prices between $30 and $36 is a consistent pattern through the run-up. Notably, founder and CEO Andrew Dudum remains the second-largest individual holder at 7.8% of shares, with a modest add of 69,000 shares reported through mid-June — the one counterweight to the broader executive selling trend.
The setup heading into August 3 is therefore less about whether HIMS is growing and more about whether the company can offer any clarity on the regulatory path for compounded GLP-1s and demonstrate that the Novo partnership broadens rather than concentrates its commercial exposure.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
